ATTY DKT NO. SERIAL NO. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE T103 1530.1 10/607,930 APPLICANT Bhatti, et al. FILING DATE **GROUP** SUPPLEMENTAL INFORMATION DISCLOSURE 06-27-03 1614 STATEMENT BY APPLICANT U.S. PATENT DOCUMENTS DOCUMENT NAME CL. SUBCL. **FILING DATE EXAMINER** DATE IF APPROP. INITIAL NO. 16 Oct. 2002 Pl US 2003/ Dahmann, et al. 0171359A1 FOREIGN PATENT DOCUMENTS DOCUMENT NO. DATE COUNTRY CL. SUBCL TRANSLATION YES NO 12 Jan 2000 Fl EP 0 970 957 A1 F2 GB 2 142 332 A 16 Jan 1985 3 May 2001 F3 WO 01/30780 A2 and A3 FO WO 01/66546 A1 F4 13 Sept. 2001 OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) Mukund, M. M., et al., "Spirocyclic Nonpeptide Gycoprotein IIb-IIIa Antagonists. Part 3: Synthesis and SAR D1 Ra of Potent and Specific 2.8-Diazaspiro[4.5]decanes," Bioorganic & Medicinal Chemistry Letters, 12(7): 1103-Smyth, M.S., et al., "Spirocyclic Nonpeptide Glycoprotein Iib-IIIa Antagonists. Part 1: Design of Potent and D2 Ø Specific 3,9-Diazaspiro [5.5]undecanes," Bioorganic & Medicinal Chemistry Letters, 11(10): 1289-1292 (2001). PARTIAL INTERNATIONAL SEARCH REPORT (7 November 2003). RP/ D3 DATE CONSIDERED **EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 4 2004 DEP

FORM PTO-I SECOND S EXAMINER INITIAL	SUPPLE	PATENT AND TO THE PATENT AND TO THE PATENT BY DOCUMENT NO.	TRADEM FORMA APPLI	ARK OFFI  ATION D  ICANT  J.S. PATEN	CE	APPI Bhatt FILII 06-2	Y DKT NO. 1530.1 LICANT ti, et al. NG DATE 7-03	10	ROUI	FILIN	IG DATE
			FOR	EIGN PAT	TENT DOCUME	NTS					
	DOCUMENT NO. DATE COUNTRY		XY.	CL.	SUBCL		RANS YES	NO			
			<u> </u>		. :				+	-	
									+		
		OTHER DO	CUMENT	ΓS (Incl. A	uthor, Title, Date	, Pertin	ent pages, etc	e.)			
RO	D1	Mullen, G., et al. Restricted Analo Receptor," J. Me	, "(—)-Spi gue of Ac d. Chem.,	iro[1-azabio etylcholine 43(22): 40	cyclo[2.2.2]octane , Is a Highly Selec 45-4050 (2000).	-3,5'-ox tive Ful	azolidin-2'-or	ne], a Coi	nform otinic	ational Acety	ly Icholine
16	D2	INTERNATION	INTERNATIONAL SEARCH REPORT (6 April 2004 ).								
EXAMINER		1		<del> </del>	I DAT	E CON	SIDERED	- 1	- 1-		
DAMMINER		KN	Now		DATE			9/2:	3/02	<i>t</i>	
		itation considered, considered. Includ						lraw line	throu	gh cita	tion if not

					T					
FORM PTO-1449 U.S. DEPARTMENT OF COL			ATTY DKT NO.			SERIAL NO.				
PATENT AND TRADEMAR			K OFFICE	T103 15			10/60	7,930		
/	<b>~</b> 60/				APPLIC					
001 2 8 20	אַ נון				Bhatti,					
E 55.	ĄN	FORMATION	DISCLOS	URE	FILING			GROU	JР	
\ \( \tag{2} \)	્ર,⊱ <sup>C</sup> ST	ATEMENT BY	Y APPLICA	ANT	06-27-0	3		1614		
TRADE!	À.A.									
	<del></del>			PATENT DOCUMENTS		T				
EXAMINER		DOCUMENT	DATE	NAME	,	CL.	SU	BCL.	l l	NG DATE
INITIAL		NO.				<u> </u>			IF A	PPROP.
RO	P1	3,282,947	11/1966	Grogan, et al.		260	293			
RA	P2	4,922,901	05/1990	Brooks, et al.		128	203.	.26		
ps.	P3	5,187,166	02/1993	Kikuchi, et al.		514	249			
PO	P4	5,583,140	12/1996	Bencherif, et al.		514	299		<u> </u>	
120	P5	5,597,919	01/1997	Dull, et al.		544	242			
R	P6	5,604,231	02/1997	Smith, et al.		514	256		<u> </u>	
R³	P7	5,616,716	04/1997	Dull, et al.		546	300			
R)	P8	5,663,356	09/1997	Ruecroft, et al.		546	300			
R	P9	5,672,601	09/1997	Cignarella		514	249	-	<u> </u>	
Ŕ	P10	5,733,912	03/1998	Wasicak, et al.		514	253			
Ø	P11	5,852,041	12/1998	Cosford, et al.		514	351			
হ	P12	6,022,868	02/2000	Olesen, et al.		514	210			
ko	P13	US 2003/	05/2003	Czollner, et al.		514	217.	.01	1	
		0092700								
						:		·		
			·							
									I	
	,									
				GN PATENT DOCUMEN	ITS	<del></del>	T	<del></del>		
		DOCUMENT	DATE	COUNTRY		CL.	SUB		TRANS	LATION
		NO.						-  -		
0 877	<b>D</b> 1	DD 0.007.050	01/1000	77				-	YES	NO
Pro C	Fl	EP 0 297 858	01/1989	EP			ļ <u> </u>			
₩ / 100 / 1	F2	EP 0 360 390	03/1990	EP		ļ	ļ			
PO	F3	EP 0 417 631	03/1991	EP		<u> </u>		_ -	-	<u> </u>
<b>P</b>	F4	GB 2 295 387	05/1996	GB	<del> </del>			-		
9,0	F5	WO 94/08992	4/1994	WO		ļ	<b> </b>			<u> </u>
(4)/ (2)/	F6	WO 96/31475 /	10/1996	WO		<del></del>	ļ	-		ļ
83/	F7	WO 96/40682	12/1996	WO						
Riv	F8	WO 97/40049	10/1997	WO (See published Engli						
·			]	language related applicati	on P13					
	770	1110 00/05510	06(1000	above)	· <u>.</u>		<u> </u>			
- 10 30	F9	WO 98/25619	06/1998	WO		ļ	<b> </b>	<b></b>  -		<del> </del>
104/	F10	WO 99/21834 -	05/1999	WO		ļ	ļ			
					<del></del>	<u> </u>	-			
			1			<u> </u>	<b> </b>	-		) ————————————————————————————————————
EVAMPER				<u> </u>	001101		L			
EXAMINER		RDCS	a Λ'	DATE	CONSID	EKED A	12.21	04		
						DERED 	- 1	<u> </u>	·	
EXAMINER:	Initial if	citation considered,	whether or no	ot citation is in conformance	e with M	PEP 609;	draw lin	e thro	ugh cita	tion if not
in conformance and not considered. Include copy of this form with next communication to applicant.										

CODE	PATO-144	D. LLC DEDARTMENT OF COMMERCE	ATTY DUT NO	SERIAL NO					
North	K1 0-144	9 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DKT NO. T103 1530.1	SERIAL NO. 10/607,930					
<b>/</b> /	£.	FATENT AND TRADEMARK OFFICE		10/007,930					
OCT 28	3003	<b>)</b>	APPLICANT Bhatti, et al.						
g UCI ZO		INFORMATION DISCLOSURE	FILING DATE	GROUP					
2001 20			06-27-03	1614					
2	STATEMENT BY APPLICANT 06-27-03 1614								
	OTHER DOSUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.)  On / D1 Abramovitch, R.A., editor, "Pyridine and Its Derivatives," Supp. Part Three, pp. 3-5, in Chemistry of								
RO	DI	Heterocyclic Compounds, Volume 14 (Interscience Publishers, 1974).							
B	D2	Adamcik, J.A., and E.J. Miklasiewicz, "Cyanoethylation. I. Weakly Basic Catalysts in the Reaction of Acrylonitrile with Active Methylene Compounds," J. Org. Chem. 28: 336-339 (1963).							
B	D3	Arneric, S., et al., "Preclinical Pharmacology of ABT-418: A the Potential Treatment of Alzheimer's Disease," CNS Drug I	Rev., 1(1): 1-26 (1995).						
RO	→ D4	Arneric, S.P., et al., "Cholinergic channel modulators as a not Exp. Opin. Invest. Drugs, 5(1): 79-100 (1996).							
PR	D5	Bannon, A.W., et al., "Broad-Spectrum, Non-Opioid Analges Nicotinic Acetylcholine Receptors," Science, 279: 77-81 (199		Modulation of Neuronal					
RO	D6	Bencherif, M., et al., "RJR-2403: A Nicotinic Agonist with C Pharmacol. Exper. Therapeutics, 279(3): 1413-1421 (1996).		ro Characterization," J.					
RO	.D7	Berkowitz, D.B., and M.K. Smith, "Enantiomerically Enriche Chiral Alanine-Derived Dianion with a High Diastereofacial							
Po	D8	Brioni, J.D., et al., "The Pharmacology of (-)-Nicotine and N Pharmacol., 37: 153-215 (1997).							
Ro	D9	Burger, A., et al., "Some Derivatives of Tetrahydropyran as F Soc., 72: 5512-5515 (1950).	Potential Pharmacodyna	mic Agents," J. Am. Chem.					
PO	D10	Cheng, Y., and W.H. Prusoff, "Relationship Between the Inhibition Constant (K <sub>1</sub> ) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I <sub>50</sub> ) of an Enzymatic Reaction," <i>Biochem. Pharmacol.</i> 22(23): 3099-3108 (1973).							
Re	D11 ,	Chiari, A., et al., "Sex Differences in Cholinergic Analgesia I Females," Anesthesiology, 91(5): 1447-1454 (1999).	: A Supplemental Nicor	inic Mechanism in Normal					
N	D12	Ciblat, S., et al., "A new route to 2-spiropiperidines," Tet. Let	t., 42: 4815-4817 (2001	).					
ર	D13	Clarke, K., and K. Rothwell, "A Kinetic Study of the Effect o	f Substituents on the Ra	nte of Formation of					
2		Alkylpyridinium Halides in Nitromethane Solution," J. Chem.							
RO	D14	Comins, D.L, and M.O. Killpack, "Lithiation of Methoxypyri Chem., 55(1): 69-73 (1990).	dines Directed by α-An	nino Alkoxides," J. Org.					
p	D15	Cosford, N.D.P., et al., "(S)-(-) 5- Ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine Maleate (SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors," J. Med. Chem., 39(17): 3235-3237 (1996).							
RP	D16	Culbertson, T.P., et al., "Quinolone Antibacterial Agents Sub- Synthesis and Structure-Activity Relationships," J. Med. Cher							
PO	D17	Damaj, M.I., et al., "Analgesic Activity of Metanicotine, A Selective Nicotinic Agonist," Society for Neuroscience, 23: 669 ABSTRACT 266.9 (1997).							
Ro	D18	Damaj, M.I., et al., "Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist," J. Pharmacol. Exp. Ther., 291(1): 390-398 (1999).							
R	D19	Decina, P., et al., "Cigarette Smoking and Neuroleptic-Induce (1990).	ed Parkinsonism," Biol.	Psychiatry, 28(6): 502-508					
r)	D20	Elliott, J.M., et al., "Serine Derived NK1 Antagonists 2: A Ph Binding," Bioorg. Med. Chem. Lett., 8: 1851-1856 (1998).	armacophore Model fo	r Arylsulfonamide					
Ka	D21	Fornicola, R.S., et al., "A New Synthesis of α-Amino Acid D	erivatives Employing N	Methyl Nitroacetate as a					
-	D22 Cosin M. Lot al Complete and County State of County State								
RD	DEL	Type-II β-Turn Mimic," J. Org. Chem., 58(8): 2334-2237 (19	_	uic (A)-4.4-Spiro Laciain					
D22 Comin M.L. and D.L. Jahrenn "Daving Country" and Co. Co., 15, 14, 1, 1, C. N. 10, 10, 11									
P		System as a Type II β-Turn Peptidomimetic," J. Amer. Chem.							
···			200., 11.(20). 0170-0	, 05 (17)2).					

•				Page 3 of 5			
FORUM	RTO-144	9 U.S. DEPARTMENT OF COMMERCE	ATTY DKT NO.	SERIAL NO.			
PATENT AND TRADEMARK OFFICE			T103 1530.1	10/607,930			
	6		APPLICANT				
OCT 2 8 20	103 m		Bhatti, et al.				
001 2 0 5	ទ្ធ	INFORMATION DISCLOSURE	FILING DATE	GROUP			
_	<i>₩</i>	STATEMENT BY APPLICANT	06-27-03	1614			
PADEN	pB24	Gibson, S., et al., "Principal Components Describing Biologic		cular Diversity of			
gv .	D25	Heterocyclic Aromatic Ring Fragments," J. Med. Chem., 39(20): 4065-4072 (1996).  Grogan, C.H., et al. "Spiranes. VII. Neuroleptics Derived from Azaspiranes," J. Med. Chem., 8: 62-73 (1965).					
<b>β</b> Σ	D26	Hall, G.H., and D.M. Turner, "Effects of Nicotine on the Release of <sup>3</sup> H-Noradrenaline from the Hypothalamus," Biochemical Pharmacology, 21: 1829-1838 (1972).					
cq	D27	Hamon, M., "Neuropharmacology of anxiety: perspectives as	nd prospects," TiPS, 15:	36-39 (1994).			
	D28	Hansch, C., et al., "The Parabolic Dependence of Drug Action	n upon Lipophilic Char	acter as Revealed by a			
PP		Study of Hypnotics," J. Med. Chem., 11(1): 1-11 (1967).		•			
fix	D29	Hansch, C., et al., "A Survey of Hammett Substituent Consta Rev., 91(2): 165-195 (1991).	ints and Resonance and	Field Parameters," Chem.			
RP	D30	Hansen, M.M., et al., "An Enantioselective Synthesis of Cis 63(3): 775-785 (1998).	Perhydroisoquinoline L	Y235959," J. Org. Chem.,			
\$D	D31	Harsing, Jr., L.G., et al., "Dopamine Efflux from Striatum Al Desensitization," J. Neurochem., 59(1): 48-54 (1992).	fter Chronic Nicotine: E	vidence for Autoreceptor			
	D32	Hartwig, J.F., et al., "Room-Temperature Palladium-Catalyze	ed Amination of Aryl B	romides and Chlorides and			
RO	1	Extended Scope of Aromatic C-N Bond Formation with a C					
•		5580 (1999).	,				
	D33	Hertog, H.J.D., et al., "The Directive Influence of the N-Oxid	le Group During the Ni	tration of Derivatives of			
Ø		Pyridine N-Oxide (IV) ) Nitration of 3-bromo-5methoxy- an					
•		Trav. Chim. Pays-Bas, 74(8/9): 1171-1179 (1955).		<i>"</i>			
	D34	Hery, F., et al., "Control of the Release of Newly Synthetized	1 3H-5-Hydroxytryptam	ine by Nicotinic and			
RP		Muscarinic Receptors in Rat Hypothalamic Slices," Naunyn-					
•		(1977).	30,,,,,,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
·	D35		nd Antihody Recogniti	on of Pentides Containing			
p	D33	Hinds, M.G., et al., "Synthesis, Conformational Properties, and Antibody Recognition of Peptides Containing β-Turn Mimetics Based on α-Alkylproline Derivatives," J. Med. Chem., 34(6): 1777-1789 (1991).					
	D36	Hoffman, J.M., et al., "Synthesis and Evaluation of 2-Pyridin					
$k \wedge$	סכע						
ſΩ		Transcriptase Inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-	ethyr-o-methyrpyriain-2	(1H)-one and Analogues,			
	D27	J. Med. Chem., 36(8): 953-966 (1993).	acantana na Tananta fan l	Drug Diagonama 2 I Mad			
Po	D37	Holladay, M.W., et al., "Neuronal Nicotinic Acetylcholine R Chem, 40(26): 4169-4194 (1997).	eceptors as Targets for	Drug Discovery," J. Mea.			
40	D20		lines " I Chan Co. 7	777 7292 (10(5)			
<u> 120                                   </u>	D38	Holland, A. et al., "Isothiazoles. Part IX. Isothiazolopyrimic		<u> </u>			
ro	D39	Hughes, D.L., "The Mitsunobu Reaction," Org. React., 42: 3		L. (00/1), 100 1/4			
Ø	D40	Hughes, D.L., "Progress in the Mitsunobu Reaction. A Review	ew," Org. Prep. Proced	. Int., 28(1): 129-164			
	5.41	(1996).					
Ro.	D41	Islam, A.M., and R.A. Raphael, "A Direct Transformation of	cycloHexanones into b	icyclo [5: 3: 0] <i>Dec-7-en-9-</i>			
		ones," J. Chem. Soc., 3151-3154 (1955).					
Ki	D42	Kim, K., et al., "Novel Bicyclic Lactams as XaaPro Type VI	β Turn Mimics: Design	n, Synthesis and			
·		Evaluation," J. Org. Chem., 61(9): 3138-3144 (1996).					
R	D43	Lall, M.S., et al., "Serine and Threonine β-Lactones: A New	Class of Hepatitis A V	irus 3C Cysteine Proteinase			
<u> </u>		Inhibitors," J. Org. Chem., 67(5): 1536-1547 (2002).					
0.	D44	Latli, B., et al., "Novel and Potent 6-Chloro-3-pyridinyl Liga	nds for the \alpha 4\beta 2 Neuro	nal Nicotnic Acetylcholine			
Ra		Receptor," J. Med. Chem., 42(12): 2227-2234 (1999).	•	•			
An	D45	Lavand'homme, P., and J.C. Eisenach, "Sex Differences in C	holinergic Analgesia II	Differing Mechanisms in			
P		Two Models of Allodynia," Anesthesiology, 91(5): 1455-146					
mB	D46			Vivo Characterization." J. P.			
pA.	~ .0	Lippiello, P.M., et al., "RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization," J. P. E. T., 279(3): 1422-1429 (1996).					
0-	D47		7 Diazaspirold AlMona	ne-2 6-Dione " Call Crack			
p	ידע	Majer, Z., et al., "Synthesis and Absolute Configuration of 1,7 Diazaspiro[4,4]Nonane-2,6-Dione," Coll. Czeci Chem. Comm., 47(3): 950-960 (1982).					
· · · · · · · · · · · · · · · · · · ·	D48	Old, D.W., et al., "A Highly Active Catalyst for Palladium-C	atalyzed Cross Countin	a Reactions: Poom			
fe	סייע						
Temperature Suzuki Couplings and Amination of Unactivated Aryl Chlorides," J. Am. Chem. Soc., 120(37): 9722-9723 (1998).							
		1 7 <i>122</i> -7 <i>12</i> 3 (1778).					

٩				Page 4 of 5			
FORM	PTO-144	9 U.S. DEPARTMENT OF COMMERCE	ATTY DKT NO.	SERIAL NO.			
OIPE	_	PATENT AND TRADEMARK OFFICE	T103 1530.1	10/607,930			
/o., ~			APPLICANT				
1	.c./		Bhatti, et al.				
OCT 2 8 2	<sub>.m</sub> ල/ ි	INFORMATION DISCLOSURE	FILING DATE	GROUP			
ן טנו 2 ס בו	<b>m</b>	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	06-27-03	1614			
20/	D49	Onaivi, E.S., et al., "Chronic Nicotine Reverses Age-Associa	ted Increases in Tail-Fli	ck Latency and Anxiety in			
A Distriction	D50	Rats," Life Sciences, 54(3): 193-202 (1994).					
Ro		Overberger, et al., "Absolute Configuration of 2,7 Diazaspiro[4.4]nonane. A Reassignment," J. Org. Chem., 46(13): 2757-2764 (1981)					
Ps	D51	Overman, L.E., and R.M. Burk, "A Convenient Synthesis of Formation of Unstable Formaldehyde Imines," <i>Tet. Lett.</i> , 25(					
,	D52	Pedersen, M.L., and D.B. Berkowitz, "Formal α-Vinylation of					
R		Equivalent," J. Org. Chem., 58(25): 6966-6975 (1993).					
<i>r</i> -	D53	Pomerleau, O.F., et al., "The Effects of Cigarette Smoking or	Pain and Anxiety," Ad	dictive Behaviors, 9: 265-			
<i>K</i> >		271 (1984).	,,				
	D54	Pullan, R.D., et al. "Transdermal Nicotine for Active Ulcerati	ve Colitis," New Engla	nd J. Med., 330(12): 811-			
K		815 (1994).	, ,	, , ,			
1/1	D55	Radziszewski, J.G., et al., "Twisted Si=N Bonds: Matrix Isol	lation of Bridgehead Sil	animines," J. Am. Chem.			
1 10		Soc., 115(18): 8401-8408 (1993).		,			
	D56	Ranganathan, D., et al., "Nitroethylene: A Stable, Clean, and	Reactive Agent for Or	ganic Synthesis," J. Org.			
P		Chem., 45(7): 1185-1189 (1980).					
	D57	Rapier, C., et al., "Stereoselective Nicotine-Induced Release	of Dopamine from Stria	tal Synaptosomes:			
Ro		Concentration Dependence and Repetitive Stimulation," J. Ne					
£ 2	D58	Reiter, L.A., "Synthesis of 4(5)-Acyl-, 1-Substituted 5-Acyl-,					
K		Aminosioxazoles," J. Org. Chem., 52(13): 2714-2726 (1987).		<b>,</b>			
10	D59	Ricciardi, F.J., and P.H. Doukas, "Facile Synthesis of Styrlqu		eles, 24(4): 971-977 (1986).			
<u> </u>	D60	Rice, L.M., et al., "Spiranes. V(1) A Synthetic Route to Sym					
R.	- 00	undecanes," J. Het. Chem., 1(3): 125-127 (1964).	,				
	D61	Rowell, P.P. and D.L. Winkler, "Nicotinic Stimulation of [3 H	Il Acetylcholine Releas	e from Mouse Cerebral			
l RP	201	Cortical Synaptosomes," J. Neurochem., 43(6): 1593-1598 (1					
<u> </u>	D62	Sanberg, P.R., et al., "Nicotine Potentiation of Haloperidol-In	duced Catalensy: Stria	tal Mechanisms."			
FO	-02	Pharmacol. Biochem. & Behavior, 46: 303-307 (1993).		······································			
· · · · · · · · · · · · · · · · · · ·	D63	Sandor, N.T., et al. "Effect of nicotine on dopaminergic-choli	nergic interaction in the	striatum." Brain Res., 567:			
Ro	202	313-316 (1991).	8				
	D64	Selnick, H.G., et al., "Preparation and Trapping of 3-Lithium-	-O-Lithiophenoxide," T	et. Lett., 34(13): 2043-2046			
fu		(1993).	=				
·	D65	Smith, P.W., et al., "New Spiropiperidines as Potent and Sele	ctive Non-Pentide Tach	ykinin NK, Receptor			
Ka		Antagonists," J. Med. Chem., 38(19): 3772-3779 (1995).		,			
Ra	D66	Süess, R. and A.G. Sandoz, "Regiospezifische Reduktionen	on 1.3.3-trisubstituierte	en Succinimiden mit			
fω		Diboran," Helv. Chim. Acta, 60: 1650-1656 (1977).	on 19090 andaomaidi				
	D67	Sury, E., and K. Hoffmann, "Über Alkylenimin-Derivate. Bei	trag zur Kenntnis der D	Diaza-spiro-undecane " Holy			
l fa	יטע ן	Chim. Acta, 36: 1815-1820 (1953).	uag zur Kennuns uch D	ruzu-spiro-unuccano, 11etv.			
· · · · ·	D68	Thomas, J. and D. Clough, "The Preparation and Measurement	nt of the Surface Activit	ty of a Series of 4-Alkyl-			
Ko	200	1,1'-Spirobipiperidinium Bromides," J. Pharm. Pharmacol., 1		of a porior of 4-triality			
	D69	Toth, E., et al., "Effect of Nicotine of Extracellular Levels of		essed by Microdialysis in			
fo	703	Various Brain Regions: Role of Glutamic Acid," Neurochem.					
<del></del>	D70	Tripathi, H.L., et al., "Nicotine-Induced Antinociception of R					
ps	5,0	Levels," J. Pharmacol. Exp. Ther., 221(1): 91-96 (1982).	and traice. Correlati	on with Meotific Diam			
D71 Visit F.C. "A stable bliss release from spinos ais illum by government stip conclion stimulants and gotter							
l pa	like polypeptides," Br. J. Pharmac., 47: 765-777 (1973).						
· · · · · · · · · · · · · · · · · · ·	D72	Wagaw, S. and S.L. Buchwald, "The Synthesis of Aminopyri	dines: A Mathod E1	oving Palladium Catalyzad			
Ø	אוע	1	-	oying ranaulum-Calalyzed			
<del></del>	D73	Carbon-Nitrogen Bond Formation," J. Org. Chem., 61(21): 7		Pharmaconsychiat 21:			
K	כוט	Wagner, B., et al., "Does Smoking Reduce the Risk of Neuro	iepue rarkinsonoids?,"	r нагтасорѕустаю, 21:			
<u> </u>		302-303 (1988).					

FORM	PTO-144	9 U.S. DEPARTMENT OF COMMERCE	ATTY DKT NO.	SERIAL NO.
IPE		PATENT AND TRADEMARK OFFICE	T103 1530.1	10/607,930
0,,	4		APPLICANT	
Y	505		Bhatti, et al.	
OCT 28	2003 L	INFORMATION DISCLOSURE	FILING DATE	GROUP
		STATEMENT BY APPLICANT	06-27-03	1614
10 PO	D749	Wittekind, R.R., and C. Weissman, "Synthesis of the 1,8-Dia	zaspiro [4.5] decane Syste	em." J. Het. Chem., 9(1):
Con the second	1.07	111-113 (1972).	,	,
$\omega$	D75	Williams, M., et al., "Neuronal Nicotinic Acetylcholine Rece	ptors," Drug News Perspe	ec., 7(4): 205-223 (1994).
R	D76	Zhu, J., et al. "Asymmetric Synthesis. 29. Preparation of 1,8	-Diazaspiro [5.5] undecan	e Derivatives," J. Org.
		Chem., 58(23): 6451-6456 (1993).		
B	D77	Zwart, C., and J.P. Wibaut, "Chemical Behaviour of 3-Amine		
	<u></u>	of (3-Pyridyl)-Pyrazolones." Recueil Trav. Chim. Pays-Bas,		
Ro	D78	Delphion Printout – Bibliographic Data for EP 0417 631 A2	(Document F3) shows De	rwent English language
	<u> </u>	abstract. Oct. 21, 2003.		
	<del></del>			
	-			
		, v		
				· · · · · · · · · · · · · · · · · · ·
			<del>-</del>	**************************************
EXAMINE	R	DATE	CONSIDERED	
		Rollsan DATE	9/2	3/04
			<del>-</del>	
EXAMINE	R: Initial	l if citation considered, whether or not citation is in conformance	ce with MPEP 609; draw l	ine through citation if not

in conformance and not considered. Include copy of this form with next communication to applicant.